Current management of relapsing-remitting multiple sclerosis.

about

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients' peripheral blood.Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.

P2860

Q35939675-A71CD07D-7F03-4E9C-9E03-0009A62E5C3E Q38629714-EC1E6789-8B81-45C3-B3F8-C1BEAFF3FFDC Q49712050-0CAF5D74-570D-471F-AD44-7257B9FFF7C9

P2860

Current management of relapsing-remitting multiple sclerosis.

Item

http://www.wikidata.org/entity/Q38258818

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Current management of relapsing-remitting multiple sclerosis.

@en

type

Item

label

Current management of relapsing-remitting multiple sclerosis.

@en

prefLabel

Current management of relapsing-remitting multiple sclerosis.

@en

P1476

Current management of relapsing-remitting multiple sclerosis.

@en

P2093

E A McDonald

http://www.w3.org/2001/XMLSchema#string

I B Wilson

http://www.w3.org/2001/XMLSchema#string

L Sedal

http://www.w3.org/2001/XMLSchema#string

P2860

Symptomatic therapy and neurorehabilitation in multiple sclerosis

FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Fingolimod for multiple sclerosis.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.

Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Natural history of multiple sclerosis: early prognostic factors.

Multiple sclerosis: current treatment algorithms.

P304

950-957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.12558

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25302718

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis

Current management of relapsing-remitting multiple sclerosis.

about

P2860

P2860

Current management of relapsing-remitting multiple sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921